Morton Grove Pharmaceuticals, Inc. FDA Inspection Record
Morton Grove Pharmaceuticals, Inc. is an FDA-inspected facility (FEI 1420913) located in Morton Grove, IL, US. RegDataLab tracks 6 FDA inspections and 2 compliance actions at this facility.
What FDA found at this site
- Latest inspection
- Feb 5, 2016: Official Action Indicated (OAI)
- Inspections on record
- 6 (1 OAI, 4 VAI, 1 NAI)
- Last OAI inspection
- Feb 5, 2016
- Warning letters
- 1 listed by FDA for this FEI, latest Feb 17, 2017
- Form 483 and inspection documents
- 1 in FDA's reading room
- Recalls as the recalling firm
- 13, latest Feb 21, 2022
- Import refusals
- 2
Inspections and what FDA cited
| Date | Result | What FDA cited |
|---|---|---|
| Feb 5, 2016 | Official Action Indicated (OAI) | No citations listed |
| Mar 26, 2014 | Voluntary Action Indicated (VAI) | No citations listed |
| Apr 12, 2011 | Voluntary Action Indicated (VAI) | SOPs not followed / documented (21 CFR 211.100(b)) Investigations of discrepancies, failures (21 CFR 211.192) Approval and review of procedures (21 CFR 211.100(a)) Procedures to be written and followed (21 CFR 211.198(a)) |
| Mar 24, 2010 | Voluntary Action Indicated (VAI) | Identity Testing of Each Component (21 CFR 211.84(d)(1)) Valid stability test methods (21 CFR 211.166(a)(3)) Complaint Handling Procedure (21 CFR 211.198(a)) |
| Sep 17, 2009 | No Action Indicated (NAI) | No citations listed |
| Mar 17, 2009 | Voluntary Action Indicated (VAI) | Test method modification records do not include (21 CFR 211.194(b)) Failure to meet specifications (21 CFR 314.81(b)(1)(ii)) |
Recalls
| Date | Class | Recall | Product and reason |
|---|---|---|---|
| Feb 21, 2022 | Class II | D-0713-2022 | Dexamethasone Elixir, USP 0.5 mg/5 mL, Net: 8 fl oz (237 mL) bottle, Rx only, Manufactured… Failed Impurities/Degradation Specifications: higher than permissible levels of unknown impurities were found in the drug product. |
| Sep 3, 2021 | Class II | D-0814-2021 | Promethazine Syrup Plain, 6.25 mg/5 mL (Promethazine Hydrochloride Syrup, USP), 1 Pint… and 2 more products CGMP Deviations: Potential concern with products manufactured using liquid sugar batches contaminated with microbial organisms. |
| Dec 9, 2020 | Class II | D-0174-2021 | Hydroxyzine Hydrochloride Oral Solution, USP (Syrup), 10 mg/5 mL, packaged in a) 4 fl oz… Failed Impurities/Degradation Specification: OOS for the following - unknown degradant/impurity, 4-chorobenzophenone, and for total… |
| Sep 23, 2019 | Class II | D-0130-2020 | Prednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, packaged in a 8 fl oz (237 mL)… Failed Impurities/Degradation Specifications - failed specs for Prednisolone Impurity 14 |
| Jul 24, 2018 | Class II | D-1042-2018 | Prednisolone Sodium Phosphate Oral Solution, 15 mg/5 mL, 8 fl oz (237 mL) Bottle, Rx only… Defective Container: Tamper Evident foil seal not completely intact. |
| Aug 10, 2017 | Class II | D-1125-2017 | Amoxicillin and Clavulanate Potassium for Oral Suspension, USP, 250/62.5 mg per 5 mL, 100… Presence of Foreign Substance: customer complaint of blue foreign material identified as a portion of a nitrile glove was discovered in… |
| Dec 15, 2015 | Class III | D-0571-2016 | Lindane Lotion, USP 1%, For External use Only, Rx Only, 2 fl oz (60 mL) bottle, MGP, NDC… Super-Potent Drug: Out of Specification Assay test results were reported for stability samples. |
| Oct 13, 2006 | Class III | D-400-7 | Prednisolone Sodium Phosphate Oral Solution, 5 mg/5 mL, 4 fl oz bottles, Rx only, NDC… One individual unknown impurity level exceeds specification |
| Dec 2, 2005 | Class II | D-069-6 | Prednisolone Oral Solution, USP 15 mg/5 mL (formerly Prednisolone Syrup, USP 15 mg/5 mL)… Degradant/Impurity level exceeded specification requirements of not more than 0.50%. |
| Sep 13, 2004 | Class II | D-278-4 | Phenytoin Oral Suspension, USP, 125 mg/5 mL, Morton Grove Pharmaceuticals, Inc., Morton… and 1 more product Superpotent: Super-potency of the active ingredient |
Form 483s and inspection documents
FDA record score
15 of 100. A count of this site's adverse public FDA records, weighted by how recent each one is. A higher number means more, or more recent, records. Each record below adds the points shown.
14 records behind this number
| Record | Date | Points x age weight | Adds |
|---|---|---|---|
| Warning letter on FDA's dashboard, which does not show close-outs | Feb 17, 2017 | 30 x 0.25 | 7.5 |
| Class II recall D-0713-2022, this FEI as the recalling firm | Feb 21, 2022 | 4 x 0.6 | 2.4 |
| Class II recall D-0814-2021, this FEI as the recalling firm | Sep 3, 2021 | 4 x 0.25 | 1 |
| Class II recall D-0174-2021, this FEI as the recalling firm | Dec 9, 2020 | 4 x 0.25 | 1 |
| Class II recall D-0130-2020, this FEI as the recalling firm | Sep 23, 2019 | 4 x 0.25 | 1 |
| Class II recall D-1042-2018, this FEI as the recalling firm | Jul 24, 2018 | 4 x 0.25 | 1 |
| Class II recall D-1125-2017, this FEI as the recalling firm | Aug 10, 2017 | 4 x 0.25 | 1 |
| Inspection classified OAI | Feb 5, 2016 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Mar 26, 2014 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Apr 12, 2011 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Mar 24, 2010 | 10 years or older, so it adds no points | 0 |
| Inspection classified VAI | Mar 17, 2009 | 10 years or older, so it adds no points | 0 |
| Class II recall D-069-6, this FEI as the recalling firm | Dec 2, 2005 | 10 years or older, so it adds no points | 0 |
| Class II recall D-278-4, this FEI as the recalling firm | Sep 13, 2004 | 10 years or older, so it adds no points | 0 |
When each source was last refreshed
| Records | Last refreshed | Source as of | Status |
|---|---|---|---|
| Inspections | Nov 17, 2026 | Newest record Nov 9, 2026 | Current |
| Inspection citations | Nov 17, 2026 | Newest record Nov 5, 2026 | Current |
| Compliance actions (warning letters, injunctions and other action types) | Nov 2, 2026 | Newest record Oct 29, 2026 | Current |
| Warning letter text | Nov 17, 2026 | Newest record Nov 10, 2026 | Current |
| Recalls (Enforcement Report) | Nov 17, 2026 | Newest record Nov 11, 2026 | Current |
| Form 483s and inspection documents | Nov 17, 2026 | Newest record Nov 16, 2026 | Current |
| Import refusals | Nov 15, 2026 | Newest record Nov 5, 2026 | Current |
Reviewing Morton Grove Pharmaceuticals, Inc. as a supplier? Request a free FDA snapshot: name up to five suppliers and get a PDF of their public FDA record, with sources and dates. You do not need an API connection. Each snapshot is prepared by hand.
Or check Morton Grove Pharmaceuticals, Inc. yourself in Claude, Cursor or ChatGPT: get the full FDA risk summary, with inspections, warning letters, Form 483s and import alerts by site.
Facility details
- Company
- Morton Grove Pharmaceuticals, Inc.
- Location
- Morton Grove, IL (US)
- Source
- inspections